Learn how to convert discs to digital with Kaleidescape and get 4K UHD titles for only $4.92! #Kaleidescape #4KUHD #DigitalConversion Donald Trump changes his mind on tariffs again Suspected mountain ...

Artificial intelligence and related technologies are evolving rapidly, but until recently, Java developers had few options for integrating AI capabilities directly into Spring-based applications.

Spring Boot is one of the most popular and accessible web development frameworks in the world. Find out what it’s about, with this quick guide to web development with Spring Boot. Spring’s most ...

I've upgraded PTC Inc. to a Buy at ~$179 per share after strong FQ4 2025 results, robust customer contract growth, and improved shareholder returns. PTC's focus on product lifecycle management, ...

Private equity firm TPG is to buy Kepware and ThingWorx from PTC for up to $725 million. It marks a final shift in PTC’s Industry 4.0 strategy, and a tightening of focus on its industrial PLM ...

PTC is selling off its IoT businesses, Kepware and ThingWorx, in order to hone its focus on SaaS and AI, according to CEO Neil Barua, as the conglomerate announced a sale of the operations to asset ...

TPG has agreed to acquire PTC’s industrial connectivity and IoT businesses. No financial terms were disclosed. Headquartered in Boston, PTC is a software company. Neil Barua serves as president and ...

With its planned acquisition of Frauscher Sensortechnik, Wabtec is pushing further into the train control market, and it hopes its PTC 2.0 concept could offer a lower-cost alternative to ETCS for ...

This software company's underlying growth rate is a lot stronger than the headline numbers indicate. ARR represents the "annualized value of our portfolio of active subscription software, SaaS, ...

PTC has evolved into an SaaS-driven industrial software leader with improved profitability, higher margins, and a stronger competitive moat. Growth has been heavily acquisition-driven, raising ...

PTC Therapeutics has long been trying to workshop its vatiquinone into a marketable treatment for Friedreich's ataxia (FA) after a phase 3 fail in 2023. Despite its efforts, the FDA has snubbed the ...

If Wall Street had any doubts about Neil Barua filling the shoes of his predecessor Jim Heppelmann as chief executive at PTC, those doubts went out the (computer-designed) window last week. The Boston ...